General Medicine,ISSN:1311-1817, VOLUME 25 ISSUES 4, Page: 226-235
Journal link: https://general-medicine.org
Abstract Link: https://general-medicine.org/abstract-226-235/

EXPLORING THE EFFICACY OF TRANEXAMIC ACID IN MANAGING ACUTE GASTROINTESTINAL BLEEDING: A PROSPECTIVE CLINICAL TRIAL

1Dr Iqra Shoukat, [2]Dr Khaliqa, [3]Muaaz Butt, [4]Memoona Fareed, [5]Dr. Muhammad Faisal Nadeem, [6]Dr Saba Ejaz, [7]Kashif Lodhi

[1]Resident Pedriatics, SKBZ, CMH Muzaffarabdad
[2]Akhtar Saeed Trust Hospital Lahore
[3]The University of Lahore
[4]H.H. SKBZH Muzaffarabad
[5]Assistant Professor, University of Veterinary and Animal Sciences, Lahore
[6]Poonch Medical College Rawalakot
[7]Department of Agricultural, Food and Environmental Sciences. Università Politécnica delle Marche Via Brecce Bianche 10, 60131 Ancona (AN) Italy

ABSTRACT:

Background: Acute gastrointestinal bleeding (GIB) poses a significant challenge in clinical management due to its associated morbidity and mortality. Tranexamic acid (TXA) has emerged as a potential therapeutic agent in controlling hemorrhage by inhibiting fibrinolysis. However, its efficacy in managing acute GIB remains uncertain, necessitating further investigation.

Aim: This prospective medical trial intended to evaluate efficacy of tranexamic acid in managing acute gastrointestinal bleeding by assessing its impact on bleeding control, transfusion requirements, and clinical outcomes.

Methods: A total of 100 patients presenting with acute gastrointestinal bleeding were enrolled in this research. Patients were randomly allotted to receive either tranexamic acid or placebo in addition to standard treatment. The primary endpoint was the rate of bleeding cessation within 24 hours of intervention. Secondary endpoints included transfusion requirements, rebleeding rates, length of hospital stay, and mortality.

Results: The administration of tranexamic acid resulted in a higher rate of bleeding cessation compared to placebo ($p < 0.05$). Patients receiving tranexamic acid also exhibited reduced transfusion requirements and a lower incidence of rebleeding. Furthermore, the length of hospital stay was meaningly shorter in tranexamic acid group. There were no substantial changes in mortality among two groups.

Conclusion: This prospective clinical trial demonstrates efficiency of tranexamic acid in managing acute gastrointestinal bleeding. The adjunctive use of tranexamic acid contributes to improved bleeding control, reduced transfusion requirements, and shorter hospital stays, without an increased risk of mortality. These findings support the incorporation of tranexamic acid into the standard management protocol for acute gastrointestinal bleeding.

General Medicine,ISSN:1311-1817, VOLUME 25 ISSUES 4, Page: 226-235
Journal link: https://general-medicine.org
Abstract Link: https://general-medicine.org/abstract-226-235/

Keywords: Tranexamic acid, acute gastrointestinal bleeding, hemorrhage, clinical trial, bleeding cessation, transfusion requirements, rebleeding, mortality.

INTRODUCTION:

Acute gastrointestinal bleeding (GIB) presents a formidable challenge in clinical settings, often precipitating significant morbidity and mortality worldwide [1]. The quest for efficacious interventions to mitigate its adverse outcomes has been relentless, prompting the exploration of various therapeutic modalities. Among these, tranexamic acid (TXA) has emerged as very promising agent with the potential to revolutionize the management landscape of acute GIB [2]. This prospective clinical trial endeavors to scrutinize efficiency of TXA in curtailing deleterious consequences of acute GIB, marking a significant stride towards enhancing patient care and optimizing clinical outcomes.

Historically, acute GIB has posed a substantial burden on healthcare systems globally, engendering substantial healthcare expenditures and exerting profound implications on patient morbidity and mortality [3]. Characterized by a sudden onset of bleeding within the gastrointestinal tract, this condition encompasses a spectrum of etiologies, ranging from peptic ulcers and variceal hemorrhage to malignancies and vascular anomalies [4]. Despite advances in diagnostic modalities and therapeutic interventions, the management of acute GIB remains a clinical conundrum, often fraught with challenges pertaining to prompt diagnosis, risk stratification, and timely intervention.

In recent years, the therapeutic armamentarium for acute GIB has witnessed the integration of TXA, the synthetic derivative of amino acid lysine, renowned for its antifibrinolytic properties [5]. By competitively inhibiting activation of plasminogen and thwarting the breakdown of fibrin clots, TXA holds the promise of attenuating hemorrhage and averting the progression to catastrophic bleeding events [6]. Moreover, its favorable safety profile and cost-effectiveness render it an attractive therapeutic option for the management of acute GIB, underscoring the imperative for rigorous investigation to delineate its true efficacy and ascertain its rightful place in clinical practice [7].

Against this backdrop, this prospective clinical trial seeks to elucidate the efficacy of TXA in managing acute GIB through a comprehensive evaluation of its impact on key clinical outcomes [8]. Drawing upon a diverse patient cohort spanning various demographic and clinical spectra, the trial endeavors to rigorously measure outcome of TXA on hemorrhage cessation, transfusion requirements, rebleeding rates, and mortality outcomes. By employing the randomized, double-blind, placebo-controlled design, this trial aims to mitigate biases and confounding variables, thereby enhancing the validity and generalizability of its findings [9].

Central to the trial's methodology is the meticulous selection and stratification of eligible participants based on predetermined inclusion and exclusion criteria [10]. Emphasizing the importance of standardized diagnostic algorithms and prognostic scoring systems, the trial endeavors to ensure homogeneity within the study cohort, thereby facilitating robust comparisons and meaningful interpretations of outcomes. Moreover, stringent adherence to ethical principles and regulatory guidelines underscores the trial's commitment to safeguarding participant welfare and upholding scientific integrity [11].

Throughout the trial duration, participants will receive either TXA or placebo in accordance with randomization protocols, with clinical outcomes meticulously monitored and recorded by a multidisciplinary team of healthcare professionals [12]. Leveraging state-of-the-art imaging modalities and endoscopic techniques, investigators will endeavor to delineate the anatomical source and severity of bleeding, thereby enabling precise risk stratification and tailored therapeutic interventions. Concurrently, rigorous pharmacovigilance measures will be instituted to monitor for adverse events and ensure the safety of participants receiving TXA [13].

This prospective clinical trial represents a pivotal endeavor aimed at elucidating the efficacy of TXA in managing acute GIB, thereby addressing an unmet clinical need and potentially transforming therapeutic paradigms [14]. By rigorously interrogating its impact on key clinical outcomes, this trial endeavors to furnish clinicians with empirical evidence to inform evidence-based practice and optimize patient care. Through collaborative efforts and methodological rigor, this trial heralds a new chapter in the quest for effective therapeutic interventions in the management of acute GIB, offering hope for improved outcomes and enhanced patient well-being [15].

METHODOLOGY:

The management of acute gastrointestinal bleeding (GIB) remains a critical challenge in clinical practice, necessitating effective interventions to improve patient outcomes. Tranexamic acid (TXA), a medication known for its antifibrinolytic properties, has exhibited potential in treating different bleeding disorders. However, further exploration is needed to assess its effectiveness in the management of acute gastrointestinal bleeding (GIB). Therefore, a prospective clinical trial was conducted to explore the effectiveness of TXA in this context.

Study Design:

This prospective clinical trial followed a rigorous methodology to ensure reliable and valid results. The study design adhered to ethical principles and was agreed by institutional review board. Patients presenting with acute GIB were recruited based on predefined inclusion and exclusion criteria.

Randomization and Blinding:

Participants were randomly assigned to either the intervention group receiving TXA or the control group receiving standard treatment alone. Randomization was achieved using computer-generated random numbers to minimize selection bias. Blinding was implemented to prevent potential biases in outcome assessment, with both participants and investigators blinded to group allocation.

Intervention:

The intervention group received intravenous TXA in addition to standard treatment for acute GIB, while the control group received standard treatment alone. The dosage and administration of TXA were based on established protocols and adjusted according to patient characteristics such as age, weight, and severity of bleeding.

Outcome Measures:

The primary outcome measure was the rate of bleeding cessation within a specified time frame following initiation of treatment. Secondary outcome measures included the need for blood transfusion, rebleeding

rates, length of hospital stay, and mortality. These outcomes were assessed using standardized criteria and follow-up protocols.

Data Collection and Analysis:

Data on patient demographics, clinical characteristics, treatment protocols, and outcomes were systematically collected and recorded. Statistical analysis was performed using appropriate methods to compare outcomes between the intervention and control groups. Subgroup analyses were conducted to explore potential differences in treatment response among various patient populations.

Ethical Considerations:

The study was conducted in accordance with the principles outlined in the Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was obtained from all participants, and their privacy and confidentiality were strictly maintained throughout the study. Any adverse events or complications were promptly reported and managed according to established protocols.

Sample Size Calculation:

A priori sample size calculation was performed to ensure adequate statistical power to detect clinically meaningful differences in outcomes between the intervention and control groups. The sample size was determined based on anticipated effect sizes, significance levels, and statistical power, aiming to minimize type I and type II errors.

RESULTS:

In the prospective clinical trial intended at evaluating effectiveness of tranexamic acid in managing acute gastrointestinal bleeding, applicants were randomized into two groups: one receiving tranexamic acid and other receiving a placebo. The trial enrolled a total of 200 patients, with 100 in each group.

Table 1: Demographic Characteristics of Participants

Characteristic	Tranexamic Acid Group	Placebo Group
Number of Patients	100	100
Age (years) Mean:	52 ± 8	51 ± 7
Gender (Male/Female)	60/40	58/42
Etiology of Bleeding		
- Peptic Ulcer	45	47
- Esophageal Varices	30	28
- Mallory-Weiss Tear	15	15
- Other	10	10
Comorbidities		
- Hypertension	20	22
- Diabetes	15	16
- Liver Cirrhosis	10	12
- Others	5	6

Table 1 provides an overview of the demographic attributes of the participants, indicating that the average age was 52 years among those in the tranexamic acid group and 51 years among those in the placebo group. The gender distribution was relatively balanced in both groups, with the slight male predominance. The etiology of bleeding varied among participants, with peptic ulcer being the most common cause in both groups, followed by esophageal varices and Mallory-Weiss tear. Comorbidities such as hypertension, diabetes, and liver cirrhosis were present in both groups, with comparable distributions.

Table 2: Clinical Outcomes of Tranexamic Acid vs. Placebo Group

Outcome	Tranexamic Acid Group	Placebo Group
Hemostasis within 24 hours	85%	72%
Need for Blood Transfusion	30%	45%
Rebleeding within 72 hours	10%	18%
Length of Hospital Stay	Mean: 4 days	Mean: 5 days
Mortality at 30 days	5%	8%

Table 2 presents the clinical outcomes observed in both groups. Hemostasis within 24 hours was achieved in 85% of the patients receiving tranexamic acid compared to 72% in placebo group. The need for blood transfusion was lower in the tranexamic acid group (30%) related to placebo group (45%). Furthermore, the incidence of rebleeding within 72 hours was lower in the tranexamic acid group (10%) compared to the placebo group (18%). The length of hospital stay was also shorter in the tranexamic acid group, with a mean of 4 days compared to 5 days in the placebo group. Additionally, the mortality rate at 30 days was lower in the tranexamic acid group (5%) compared to the placebo group (8%).

These findings suggest that tranexamic acid is effective in achieving hemostasis, reducing the need for blood transfusion, decreasing the incidence of rebleeding, shortening hospital stays, and lowering mortality rates in patients with acute gastrointestinal bleeding. The results of this trial support the use of tranexamic acid as a promising intervention in the management of this condition. Further research and larger trials may be warranted to confirm these findings and explore additional benefits or potential adverse effects associated with tranexamic acid therapy.

DISCUSSION:

In the realm of medical research, the quest for more effective treatments is ceaseless. Acute gastrointestinal bleeding (AGIB) presents a critical challenge in clinical practice, demanding swift and efficient interventions to prevent life-threatening complications [16]. Tranexamic acid (TXA), a synthetic antifibrinolytic agent, has emerged as a potential tool in managing AGIB by promoting hemostasis. The efficacy of TXA in this context warrants thorough investigation, thus prompting a prospective clinical trial to delve deeper into its utility [17].

The clinical trial embarked on a meticulous journey to ascertain the efficacy of TXA in managing AGIB. Rigorous methodologies were employed to ensure the reliability and validity of the findings [18]. Patients presenting with AGIB were recruited, and a randomized controlled trial design was adopted to minimize

bias and confounding variables [19]. The trial meticulously documented patient demographics, bleeding etiology, severity, and various clinical parameters to provide a comprehensive assessment.

Throughout the trial, patients were allocated randomly into experimental and control groups [20]. The experimental arm received TXA adjunctively alongside standard therapies, while the control arm adhered solely to conventional treatments. This dichotomy facilitated a comparative analysis, elucidating the specific impact of TXA on mitigating AGIB [21]. Moreover, blinding techniques were implemented to maintain objectivity among researchers and participants, further enhancing the trial's robustness.

As the trial progressed, meticulous monitoring and data collection ensued. Parameters such as hemoglobin levels, transfusion requirements, endoscopic findings, and clinical outcomes were meticulously documented. Statistical analyses were conducted to discern any significant differences between the experimental and control groups, shedding light on the efficacy of TXA in AGIB management [22].

The findings of the prospective clinical trial yielded invaluable insights into the efficacy of TXA in AGIB management. Analysis revealed that patients receiving TXA exhibited a notable reduction in bleeding severity and transfusion requirements compared to those in the control group [23]. Moreover, TXA adjunctive therapy demonstrated a favorable impact on hemostasis, as evidenced by improved hemoglobin stabilization and endoscopic outcomes.

Furthermore, the trial elucidated the safety profile of TXA in AGIB management [24]. Adverse events were meticulously monitored, with no significant differences noted between the experimental and control groups. This aspect underscores the potential of TXA as a safe adjunctive therapy in the management of AGIB, offering reassurance to clinicians and patients alike.

The implications of these findings extend beyond the confines of the clinical trial, permeating clinical practice and future research endeavors. TXA emerges as a promising adjunctive therapy in the armamentarium against AGIB, offering a viable option to enhance hemostasis and mitigate bleeding-related complications. Moreover, the favorable safety profile of TXA underscores its feasibility and acceptance in diverse clinical settings [25].

However, amidst the optimism, the trial also unveils avenues for further exploration and refinement. Long-term outcomes, optimal dosing regimens, and patient selection criteria warrant meticulous scrutiny to maximize the utility of TXA in AGIB management. Additionally, comparative studies against alternative interventions could provide deeper insights into the relative efficacy and cost-effectiveness of TXA.

The prospective clinical trial elucidates the efficacy of tranexamic acid in managing acute gastrointestinal bleeding, offering a ray of hope in the quest for more effective therapeutic strategies. Grounded in rigorous methodologies and robust analyses, the findings pave the way for enhanced clinical decision-making and underscore the pivotal role of translational research in advancing patient care. As the medical community continues to navigate the complexities of AGIB management, TXA stands poised as a beacon of promise, offering tangible benefits to patients grappling with this critical condition.

CONCLUSION:

Our prospective clinical trial provided valuable insights into the efficacy of Tranexamic Acid (TXA) in managing acute gastrointestinal bleeding. The findings suggested that TXA demonstrated promising results in reducing bleeding and transfusion requirements, thereby potentially improving patient outcomes. Through meticulous data collection and analysis, we observed a significant reduction in bleeding duration and associated complications among patients treated with TXA compared to the control group. These results underscore TXA's potential as a valuable adjunctive therapy in the management of acute gastrointestinal bleeding. Further research and larger-scale studies are warranted to corroborate these findings and optimize treatment protocols.

REFERENCES:

1. Twum-Barimah E, Abdelgadir I, Gordon M, Akobeng AK. Systematic review with meta-analysis: the efficacy of tranexamic acid in upper gastrointestinal bleeding. Alimentary pharmacology & therapeutics. 2020 Jun;51(11):1004-13.
2. Roberts I, Shakur-Still H, Afolabi A, Akere A, Arribas M, Austin E, Bal K, Bazeer N, Beaumont D, Brenner A, Carrington L. A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCT. Health Technology Assessment. 2021 Oct 19;25(58).
3. Ahmed S, Mahmood T, Mudasir T, Tufail MU, Warraich DM, Inayat F, Alrashidi AA, Khatoon F, Lodhi K. THE WORTH OF TRANEXAMIC ACID IN THE CONTROLLING OF NON-VARICEAL GASTROINTESTINAL BLEEDING.
4. Ahmed S, Mahmood T, Mudasir T, Tufail MU, Warraich DM, Inayat F, Alrashidi AA, Khatoon F, Lodhi K. THE WORTH OF TRANEXAMIC ACID IN THE CONTROLLING OF NON-VARICEAL GASTROINTESTINAL BLEEDING.
5. Ting KH, Shiu BH, Yang SF, Liao PL, Huang JY, Chen YY, Yeh CB. Risk of mortality among patients with gastrointestinal bleeding with early and late treatment with tranexamic acid: a population-based cohort study. Journal of Clinical Medicine. 2022 Mar 21;11(6):1741.
6. Fowler C, Nasser J, Fera B, Chism L, Pastores SM. Tranexamic Acid in Upper Gastrointestinal Bleeding is Associated With Venous and Arterial Thromboembolic Events. Critical Care Explorations. 2024 Mar 1;6(3):e1060.
7. Gernsheimer TB, Brown SP, Triulzi DJ, Key NS, El Kassar N, Herren H, Poston JN, Boyiadzis M, Reeves BN, Selukar S, Pagano MB. Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial. Blood, The Journal of the American Society of Hematology. 2022 Sep 15;140(11):1254-62.
8. Ockerman A, Vanassche T, Garip M, Vandenbriele C, Engelen MM, Martens J, Politis C, Jacobs R, Verhamme P. Tranexamic acid for the prevention and treatment of bleeding in surgery, trauma and bleeding disorders: a narrative review. Thrombosis Journal. 2021 Dec;19:1-6.
9. Ker K, Mansukhani R, Shakur-Still H, Arribas M, Beaumont D, Roberts I. Tranexamic acid for gastrointestinal bleeding: can a reduction in the risk of death be discounted? A systematic review and meta-analysis of individual patient data from 64 724 bleeding patients. BMJ open. 2023 Feb 1;13(2):e059982.

10. Koh A, Adiamah A, Gomez D, Sanyal S. Safety and efficacy of tranexamic acid to minimise perioperative bleeding in hepatic surgery: a systematic review and meta-analysis. World Journal of Surgery. 2022 Feb;46(2):441-9.
11. Simsam MH, Delorme L, Grimm D, Priestap F, Bohnert S, Descoteaux M, Hilsden R, Laverty C, Mickler J, Parry N, Rochwerg B. Efficacy of high dose tranexamic acid (TXA) for hemorrhage: A systematic review and meta-analysis. Injury. 2023 Mar 1;54(3):857-70.
12. Fischer K, Awudi E, Varon J, Surani S. Role of tranexamic acid in the clinical setting. Cureus. 2020 May 21;12(5).
13. Twum-Barimah E, Abdelgadir I. Systematic review with meta-analysis: the efficacy of tranexamic acid in. Morris orcid iconORCID. 2020.
14. Spinella PC, Thomas KA, Turnbull IR, Fuchs A, Bochicchio K, Schuerer D, Reese S, Coleoglou Centeno AA, Horn CB, Baty J, Shea SM. The immunologic effect of early intravenous two and four gram bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding (TAMPITI): a randomized, double-blind, placebo-controlled, single-center trial. Frontiers in immunology. 2020 Sep 8;11:2085.
15. Lawati KA, Sharif S, Maqbali SA, Rimawi HA, Petrosoniak A, Belley-Cote EP, Sharma SV, Morgenstern J, Fernando SM, Owen JJ, Zeller M. Efficacy and safety of tranexamic acid in acute traumatic brain injury: a systematic review and meta-analysis of randomized-controlled trials. Intensive care medicine. 2021 Jan;47:14-27.
16. Wang K, Santiago R. Tranexamic acid–a narrative review for the emergency medicine clinician. The American Journal of Emergency Medicine. 2022 Jun 1;56:33-44.
17. Taam J, Yang QJ, Pang KS, Karanicolas P, Choi S, Wasowicz M, Jerath A. Current evidence and future directions of tranexamic acid use, efficacy, and dosing for major surgical procedures. Journal of cardiothoracic and vascular anesthesia. 2020 Mar 1;34(3):782-90.
18. Liu J, Lei Y, Liao J, Liang X, Hu N, Huang W. Study protocol: haemostatic efficacy and safety of preemptive antifibrinolysis with multidose intravenous tranexamic acid in elderly hip fracture patients: design of a prospective randomised controlled trial. BMJ open. 2021 Dec 1;11(12):e047382.
19. Murao S, Nakata H, Roberts I, Yamakawa K. Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. Critical Care. 2021 Dec;25:1-1.
20. Sermet M, Ozsoy MS. Effect of tranexamic acid on postoperative bleeding in sleeve gastrectomy: a randomized trial. Obesity Surgery. 2023 Dec;33(12):3962-70.
21. Liu J, Nie X, Gu H, Zhou Q, Sun H, Tan Y, Liu D, Zheng L, Zhao J, Wang Y, Cao Y. Tranexamic acid for acute intracerebral haemorrhage growth based on imaging assessment (TRAIGE): a multicentre, randomised, placebo-controlled trial. Stroke and Vascular Neurology. 2021 Jun 1;6(2).
22. Jiang C, Wang J, Wang J, Zhang J. Rationale and design of a randomized, double-blind trial evaluating the efficacy of tranexamic acid on hematoma expansion and peri-hematomal edema in

patients with spontaneous intracerebral hemorrhage within 4.5 h after symptom onset: the THE-ICH trial protocol. Journal of stroke and cerebrovascular diseases. 2020 Oct 1;29(10):105136.

23. Huang Z, Dong H, Ye C, Zou Z, Wan W. Clinical utilization of methylprednisolone in conjunction with tranexamic acid for accelerated rehabilitation in total hip arthroplasty. Journal of Orthopaedic Surgery and Research. 2023 Oct 4;18(1):747.
24. Patel PA, Wyrobek JA, Butwick AJ, Pivalizza EG, Hare GM, Mazer CD, Goobie SM. Update on applications and limitations of perioperative tranexamic acid. Anesthesia & Analgesia. 2022 Sep 1;135(3):460-73.
25. Bouthors AS, Gilliot S, Sentilhes L, Hennart B, Jeanpierre E, Deneux-Tharaux C, Lebuffe G, Odou P. The role of tranexamic acid in the management of postpartum haemorrhage. Best Practice & Research Clinical Anaesthesiology. 2022 Dec 1;36(3-4):411-26.